This episode breaks down how PBMs conduct inventory audits, the sourcing and timing issues that trigger recoupments, and how pharmacies can prepare and push back.
|Articles|May 21, 2007
Latebreakers: ADHD drug given Schedule II classification
Prodrug stimulant lisdexamfetamine dimesylate (Vyvanse, Shire) will be considered a Schedule II substance, according to recent word from DEA.
Advertisement
Prodrug stimulant lisdexamfetamine dimesylate (Vyvanse, Shire) will be considered a Schedule II substance, according to recent word from DEA. This marks the final step in the approval process for the drug, which is expected to launch in the second quarter of this year. Vyvanse was approved by the FDA in February for the treatment of ADHD and is thought to have a lower abuse potential than existing stimulants used to treat the disorder.
Advertisement
Related to this article
In part 2 of our discussion with Kimberly Kue-Tsemo, PharmD, she addresses the emergence of technology and the nuances behind its actual capabilities.
In part 2, Allison Schneider, MPH, discusses PBM and 340B reform that could compound pharmacies’ burden amid ongoing Medicare drug price negotiations.
Researchers provide an update on the adverse events of special interest following patients who received 2024–2025 Pfizer-BioNTech COVID-19 vaccination.
Type 1 and type 2 diabetes reports emphasize areas where pharmacists can act now, including CGM, cardio-kidney therapies, and equitable patient access.
Kimberly Kue-Tsemo, PharmD, explores the current state of US pharmacy deserts amid ongoing reform, evolution in practice, and more.
Alyssa Eisenberg, PharmD, discusses key industry challenges and developments as community pharmacists continue to impact patient outcomes across the US.
Allison Schneider, MPH, provides expertise on how IRA drug price negotiations have impacted pharmacies in 2026 and what’s to come in the years ahead.
Advertisement
Advertisement
Trending on Drug Topics
1
Updated Diabetes Consensus Shifts Focus from Glucose Control to Whole-Person Care
2
No Added Adverse Event Risk in Pfizer-BioNTech COVID-19 Vaccine
3
What the CLARITY Study Means for Counseling on Long-Acting HIV PrEP
4
Q&A: Overlapping PBM, 340B Reform Create Uncertainty for Pharmacies
5